Moleculin Q2 2026: MIRACLE CR rates 3x control, cash runway into Q1 2027

Moleculin Biotech, Inc.

MIRACLE interim data: CR 43% (190 mg/m²) and 36% (230 mg/m²) vs 12% control; CRc 50% and 57% vs 29%.
Enrollment >80% of 90 patients; data readout Dec 2026-Feb 2027; Part B start 1H 2027.
Cash $7.3M at June 30 plus $9.3M raised post-quarter; runway into Q1 2027.
R&D expenses $5.5M in Q2 2026 vs $3.6M YoY; G&A flat at $2.1M.
No cardiotoxicity observed; ASCO data support cardiac safety profile.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.